Recombinant Human Insulin Growth Factor 1 (rhIGF-1) ( DrugBank: Human insulin )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 156 | レット症候群 | 1 |
156. レット症候群
臨床試験数 : 44 / 薬物数 : 61 - (DrugBank : 23) / 標的遺伝子数 : 57 - 標的パスウェイ数 : 83
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01777542 (ClinicalTrials.gov) | January 2013 | 23/1/2013 | Treatment of Rett Syndrome With Recombinant Human IGF-1 | Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection) | Rett Syndrome | Drug: Recombinant Human Insulin Growth Factor 1 (rhIGF-1);Drug: Placebo | Boston Children's Hospital | International Rett Syndrome Foundation | Completed | 2 Years | 10 Years | Female | 30 | Phase 2 | United States |